

Remarks

Claims 1-4, 7, 9, 13, 14, and 17-22 were pending in the subject application. By this Amendment, claim 17 has been amended, and new claims 23-25 have been added. The undersigned avers that no new matter is introduced by this amendment. Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 1-4, 7, 9, 13, 14, and 17-25 are currently before the Examiner for consideration. Favorable consideration of the pending claims is respectfully requested.


Claim 17 has been amended to remove the term "cancer" immediately after "melanoma", in order to avoid redundancy. Support for new claims 23-25 can be found, for example, at page 9, lines 1-3, and page 15, lines 7-9, of the specification.

In view of the foregoing remarks and amendments to the claims, the applicant believes that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv